The Future EU health agenda should bring EU solidarity to life

Medicines for Europe members supply most of the essential prescription medicines in Europe, accounting for 67% of dispensed medicines. These medicines cover 80% of therapy areas, including for major and debilitating diseases such as cardiovascular disease, auto-immune conditions, cancer, and diabetes, among many others.

Open

Vote to level up the European Health Union in upcoming elections

The upcoming European elections will have a significant impact on the future of health policy in Europe. EU policies and decisions can shape national health systems and influence the health and well-being of millions of citizens across Europe.

Open

European Commission Biotech initiative must spearhead next wave of EU biosimilar advances for patients and stimulate manufacturing

Biosimilar medicines were invented in Europe over 15 years ago. Since then, they have increased patient access to essential biologic medicines needed to treat the most serious of diseases like cancer, autoimmune conditions and diabetes by well over 50%.

Open

Parliament compromise on pharmaceutical legislation accelerates much needed reform

Today, the Members of the Parliament’s health committee (ENVI) adopted a compromise position on the EU Pharmaceutical legislation review (comprising of a new Pharmaceutical Directive and Regulation). The Parliament has prioritised advancing this important legislation to improve the access, availability, and affordability of medicines ahead of the EU elections in June 2024 and prevent further delays of this much needed reform.

Open

The enormous and unknown healing power of old medicines (ES)

The legislative reform being prepared by the EU plans to promote the use of already approved drugs for new ailments. This route allows to accelerate the approval of treatments and save costs in research.

Read the comment of our Director general and full Article below

Open

Parliament’s balanced stand on Unitary SPC regulation rewards innovation via an efficient Unitary SPC system that protects against access to medicines delays

The position adopted today by the European Parliament on the proposals for the Unitary Supplementary Protection Certificate (SPC) and SPC Regulation recast, led by MEP Tiemo Wolken, is a significant milestone for innovation and access to medicines across Europe in this important legislative process.

Open

Changes in medicines procurement policies urgently needed to ensure secure supply of essential medicines

Medicines for Europe’s newly published position paper explores how the current design of procurement rules in EU Member States, often aimed exclusively at reducing costs, has led to the consolidation of supply and increased risks for supply security.

Open

Health Policy Watch: Forum Discusses High Drug Prices in Wealthy Countries and Access to Medicines in Conflicts

Adrian van den Hoven, chair of the International Generic and Biosimilar Medicines Association (IGBA), which aims to foster market access for generic medicines, said that the evergreening of patent agreements artificially stretches monopolies and harms access to medicines.

Read the full Article below

Open

Joint statement Association for Accessible Medicines – Medicines for Europe ahead of 5th EU-U.S. Trade and Technology Council Ministerial meeting

Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.

Open

Court decision on Supplementary Protection Certificate (SPC) manufacturing waiver risks undermining its use

Medicines for Europe and its members are strongly concerned by the first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023.

Open